|
|
| | ARGIPRESSIN ACETATE Basic information |
| Product Name: | ARGIPRESSIN ACETATE | | Synonyms: | (CYS-TYR-PHE-GLN-ASN-CYS)CYCL-PRO-ARG-GLY-NH2 ACETATE SALT;CYS-TYR-PHE-GLN-ASN-CYS-PRO-ARG-GLY-NH2 ACETATE SALT;ANTIDIURETIC HORMONE ACETATE SALT;ARGIPRESSIN ACETATE;ARGININE VASOPRESSIN ACETATE SALT;[ARG8]-VASOPRESSIN ACETATE SALT;BETA-HYPOPHAMINE ACETATE SALT;AVP | | CAS: | 129979-57-3 | | MF: | C48H69N15O14S2 | | MW: | 1144.28 | | EINECS: | | | Product Categories: | | | Mol File: | 129979-57-3.mol |  |
| | ARGIPRESSIN ACETATE Chemical Properties |
| Melting point | 189 °C(dec.) | | storage temp. | −20°C | | solubility | Water: 1 mg/ml | | form | powder to crystal | | color | White to Light yellow | | Water Solubility | Water: 1 mg/ml |
| Hazard Codes | Xn | | Risk Statements | 20 | | Safety Statements | 36 | | WGK Germany | 3 | | F | 3-10 | | HS Code | 2937.19.0000 |
| | ARGIPRESSIN ACETATE Usage And Synthesis |
| Description | Argipressin is a peptide hormone with vasoconstrictive and antidiuretic activities that binds to the vascular arginine vasopressin receptor, V1, with Kd values of 1.31 and 1.44 nM in A7r5 rat aortic smooth muscle cells and neonatal rat cardiomyocytes, respectively. It also stimulates the intracellular release of calcium in A7r5 cells (EC50 = 5 nM). In rat models, argipressin induces hypertension and tachycardia when injected into the lateral septal nuclei at a dose of 100-400 ng and increases heart rate and mean arterial pressure (MAP) when injected into the medial amygdaloid body at a dose of 150-600 ng. | | Uses | Argipressin (Arg8-vasopressin) (acetate) binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1[1][2][3][4]. | | in vivo | Argipressin (Arg8-vasopressin) (acetate) (25 nmol/kg bw; intraperitoneal injection; once) significantly reduces overall AUC glucose values, but not increases insulin levels in mice[1]. | Animal Model: | NIH Swiss mice (adult; male; 12-14weeks)[1] | | Dosage: | 25 nmol/kg bw | | Administration: | AVP (25 nmol/kg bw; intraperitoneal injection; once) | | Result: | Reduced (P<0.001) overall AUC glucose values，but not increased insulin levels in mice. |
| | References | [1] Shruti Mohan, et al. Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival. Biochimie. DOI:10.1016/j.biochi.2019.01.008
[2] Thibonnier M, et al. Multiple signaling pathways of V1-vascular vasopressin receptors of A7r5 cells. Endocrinology. 1991 Dec;129(6):2845-56. DOI:10.1210/endo-129-6-2845
[3] Moriya T, et al. Vasopressin-induced intracellular Ca2? concentration responses in non-neuronal cells of the rat dorsal root ganglion. Brain Res. 2012 Nov 5;1483:1-12. DOI:10.1016/j.brainres.2012.08.028
[4] Keun Suk Park, et al. Role of vasopressin in current anesthetic practice. Korean J Anesthesiol. 2017 Jun; 70(3): 245–257. DOI:10.4097/kjae.2017.70.3.245 |
| | ARGIPRESSIN ACETATE Preparation Products And Raw materials |
|